Abstract: The present invention relates to nicotinamide (niacinamide) or suitable precursors or metabolites thereof and compositions thereof for use for reducing the time to resolution of one or more symptoms in patients with COVID-19 or in patients with other viral infections.
Abstract: Described herein are pharmaceutical compositions for the oral administration of nicotinamide, or a combination of nicotinamide and mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of nicotinamide or a combination of nicotinamide and mesalazine.
Type:
Grant
Filed:
April 18, 2017
Date of Patent:
April 11, 2023
Assignee:
CONARIS RESEARCH INSTITUTE AG
Inventors:
Alfred Chi Yeh Liang, Venkataramana Dingari
Abstract: The present invention relates to microcapsules comprising a core containing vitamin B3, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.
Type:
Application
Filed:
April 12, 2017
Publication date:
September 9, 2021
Applicants:
CONARIS RESEARCH INSTITUTE AG, CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL
Inventors:
Karin SCHWARZ, Julia KEPPLER, Eva-Maria THEISMANN, Jörg KNIPP, Daniela FANGMANN, Matthias LAUDES, Stefan SCHREIBER, Georg WÄTZIG
Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
Abstract: The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
Abstract: Described herein are pharmaceutical compositions for the oral administration of nicotinamide, or a combination of nicotinamide and mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of nicotinamide or a combination of nicotinamide and mesalazine.
Type:
Application
Filed:
April 18, 2017
Publication date:
May 21, 2020
Applicant:
CONARIS RESEARCH INSTITUTE AG
Inventors:
Alfred Chi Yeh LIANG, Venkataramana DINGARI
Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
Abstract: The invention provides various extended release granules of nicotinamide. Granule properties can be enhanced by the inclusion of a conductive filler.
Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
Abstract: The present invention relates to microcapsules comprising a core containing an active substance, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.
Type:
Application
Filed:
April 12, 2017
Publication date:
April 11, 2019
Applicants:
CONARIS RESEARCH INSTITUTE AG, CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL
Inventors:
Georg WÄTZIG, Karin SCHWARZ, Julia KEPPLER, Eva-Maria THEISMANN, Jörg KNIPP, Mark ELLROCHMANN, Stefan SCHREIBER
Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 GIn113 or ASn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.
Type:
Application
Filed:
June 20, 2013
Publication date:
March 13, 2014
Applicant:
Conaris Research Institute AG
Inventors:
Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, Georg H. Wätzig
Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.
Type:
Grant
Filed:
October 15, 2008
Date of Patent:
August 6, 2013
Assignee:
Conaris Research Institute AG
Inventors:
Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, Georg H. Wätzig
Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
Type:
Grant
Filed:
August 26, 2005
Date of Patent:
June 26, 2012
Assignee:
Conaris Research Institute AG
Inventors:
Dirk Seegert, Georg Wätzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
Abstract: A polypeptide-dimer built of two identical monomeric fragments comprising the domains 1 to 3 of the extracellular (soluble) part of glycoprotein (gp)130 and a certain polypeptide spacer are described, which are covalently linked with each other and which bear significant advantages concerning their production rate in host cells, their improved purification and their potential to bind to IL-6/soluble IL-6 receptor complexes. Furthermore, a pharmaceutical composition containing said dimeric molecule and various medical uses are described.